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Dear Sir,
It was with particular interest that we read the article by
Afshar-Oromieh et al. [1]. The authors developed a novel
68Ga-labelled prostate-specific membrane antigen (PSMA)-
binding small molecule, combining the well-known urea-
based inhibitory motif glutamate-urea-lysine [2] with the
lipophilic N,N′-bis[2-hydroxy-5-(carboxyethyl)-benzyl]
ethylenediamine-N,N′-diacetic acid (HBED-CC) chelator
for 68Ga [3]. The authors reasoned that the lipophilicity of
HBED-CC might improve binding to PSMA and thus en-
able positron emission tomography (PET)/CT imaging of
prostate carcinoma (PCa) [3]. Recognizing that PSMA
targeting is one of the most exciting topics of molecular
imaging and targeted therapy in prostate cancer at present,
the authors are to be congratulated on offering the first larger
patient series of 37 individuals with relapsing PCa, exam-
ined with a 68Ga-labelled PSMA inhibitor and PET/CT.
Examination of the biodistribution of the novel tracer and
capability to show presumed sites of metastatic involvement
were major intents of the study. The authors described
excellent lesion detection with impressive contrast of pre-
sumed sites of metastatic deposits of prostate cancer in 31 of
their 37 patients (83.8 %) [1].
A detailed discussion of the many clinical and technical
ambiguous aspects of the study is beyond the scope of this
letter. However, we think that in a study comprising 37
patients a discussion of 42 patients in the text needs clarifica-
tion. In addition, we cannot follow the assumption that a
prostate involved with prostate cancer and treated with local
radiation therapy and androgen deprivation therapy can be
regarded as a ‘normal prostate’. Also, interpretation of the
clinical state of patient 21 described in the legend of Fig. 7 as
harbouring probably dedifferentiated prostate cancer because
of positive pelvic nodes and a serum prostate-specific antigen
(PSA) concentration of 0.01 ng/ml is confusing as this patient
already had a Gleason score of 9 of his primary and bone as
well as soft tissue metastases (Table 1) and therapy beyond
prostatectomy is not discussed. Moreover, one of the two
positive nodes in this patient is an inguinal node, a localization
where positive nodes from PCa are very rare. Generally, a
definition of assessment criteria of assumed prostate cancer
deposits and verification by some reference standard in more
than the six histologically controlled patients described would
have been very welcome. Interestingly, the authors try to ex-
plain 68Ga-PSMA inhibitor biodistribution with rather high
tracer uptake in lacrimal and salivary glands, nasal mucosa,
liver, spleen, bowel, kidneys and bladder in the context of
known PSMA tissue expression. Avery similar biodistribution
to that described by the authors was observed in a series of
seven patients, examined with the PSMA inhibitor MIP-1072
([(S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)
ureido) pentanedioic acid) and MIP-1095 ([(S)-2-(3-((S)-1-
carboxy-5-(3-(4-iodophenyl)pentyl)ureido) pentanedioic acid)
by Barrett et al. very recently [4]. Also in this study, lesions
from PCa could be imaged with high contrast using single
photon emission computed tomography (SPECT)/CT as the
imaging technique [4]. Studying relapsing prostate cancer
with another 68Ga-PSMA inhibitor, 68Ga-DOTA-DUPA-
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ylic acid) we can confirm the very favourable imaging
properties of PSMA targeting with urea-based inhibitors
for showing metastatic disease with PET/CT (Fig. 1a), but
we observed a remarkably different biodistribution (Fig. 1b) to
that described by Afshar-Oromieh et al. [5]. We found pre-
dominant tracer uptake in kidneys, urinary tract, blood pool
and lesions from PCa (Fig. 1a) and only very faint uptake in
salivary glands and also in gynaecomastia (Fig. 1b). Interest-
ingly, a current paper by Pomper’s group using the 18F-
labelled PSMA inhibitor N-[N-[(S)-1,3-dicarboxypropyl]
carbamoyl]-4-18F-fluorobenzyl-L-cysteine (18F-DCFBC) de-
scribed a strikingly similar biodistribution to that of 68Ga-
DOTA-DUPA-Pep [6]. Thus, PSMA addressing through
urea-based inhibitors with appropriate radiolabelled peptides
seems to provide a very promising approach for targeting
various stages of PCa in patients; however, factors governing
extraprostatic tissue distribution need further careful analysis
and consideration.
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Fig. 1 a A 70-year-old patient with a history of prostatectomy because
of PCa 12 years before the examination, Gleason score 5+5, local
radiation therapy and castration-resistant PCa at presentation, PSA 3 ng/
ml. 11C-choline PET/CT showed large local recurrence and disseminated
bone marrow metastases. Completely concordant 68Ga-DOTA-DUPA-
Pep findings with disseminated bone marrow metastases confirmed by
MRI and a large local recurrence (arrow). Note normal tissue background
mostly in blood pool, uptake in kidneys and urinary tract with some urine
contamination (arrowhead) due to urinary conduit because of inconti-
nence and very faint uptake in salivary glands. Maximum intensity
projection (MIP) of a PET image of the trunk acquired 1 h after injection
of 85 MBq 68Ga-DOTA-DUPA-Pep. b A 74-year-old patient with a
history of PCa 2 years before the examination, stage II, Gleason score
3+3, androgen deprivation therapy with bicalutamide, PSA at presenta-
tion 0.2 ng/ml. 68Ga-DOTA-DUPA-Pep PET shows uptake in kidneys,
urinary tract and blood pool and faintly in salivary and lacrimal glands.
There is no evidence of tumour deposits. Interestingly, also faint uptake is
seen due to gynaecomastia (arrowheads). MIP PET as in a, 105 MBq
68Ga-DOTA-DUPA-Pep
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